Personalized chemotherapy for lung cancer based on DNA test
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if a personalized treatment plan, guided by a blood test for tumor DNA, can improve outcomes for people with untreated, surgically removable lung cancer. It combines chemotherapy with immunotherapy before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IIA to IIIB non-small cell lung cancer that hasn't been treated yet.
- Your cancer is considered removable by a team of doctors.
- If you have non-squamous cancer, it must not have certain gene mutations (EGFR/ALK).
- You are well enough to be up and about (ECOG score 0 or 1).
- Your blood counts and organ function (kidney, liver) are within a healthy range.
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized approach to combining immunotherapy and chemotherapy for people with advanced non-small cell lung cancer that does not have specific genetic changes (driver mutations). The goal is to see if tailoring treatment based on your immune system can improve outcomes.
This trial uses real-world data to study how to personalize treatment for advanced non-small cell lung cancer. It looks at medical records from 2011 to 2024 to find the best therapy approaches.
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
This trial tests a personalized combination of radiation and immunotherapy for people with locally advanced non-small cell lung cancer that has a high level of a protein called PD-L1. It aims to improve treatment by tailoring the therapy to each patient's tumor.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This Phase 2 study tests how results from blood cancer DNA tests (ctDNA) can help choose the best immune therapy approach for newly diagnosed, advanced lung cancer. It aims to improve outcomes by matching treatment decisions to a patient’s immune and blood test “profile.”
Hear when a new Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.